Tue, February 12, 2013
[ Tue, Feb 12th 2013 ]: Market Wire
Dako to Collaborate With Pfizer on Companion Diagnostics
[ Tue, Feb 12th 2013 ]: Market Wire
CML HealthCare Inc. Implements Sysmex HST-N(TM) Total Hematology Automation Systems
[ Tue, Feb 12th 2013 ]: Market Wire
Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
[ Tue, Feb 12th 2013 ]: Market Wire
Promus PREMIERa" Everolimus-Eluting Platinum Chromium Stent System Receives CE Mark Approval
[ Tue, Feb 12th 2013 ]: Market Wire
Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
[ Tue, Feb 12th 2013 ]: Market Wire
CareFusion Launches New Take-Apart Laparoscopic Scissors
[ Tue, Feb 12th 2013 ]: Market Wire
International Stem Cell Corporation Demonstrates .. ficacy Results in Metabolic Liver Disease Program
[ Tue, Feb 12th 2013 ]: Market Wire
Pfizer, Micron, NASDAQ OMX, Merck & Co, Staples, and SandRidge Energy
[ Tue, Feb 12th 2013 ]: Market Wire
Faruqi amp;; Faruqi, LLP is Investigating .. Corporation on Behalf of its Shareholders - RPTP
[ Tue, Feb 12th 2013 ]: Market Wire
Micro Imaging Technology Announces Paradigm Shift .. oviding Software-Based Identification of Microbes
[ Tue, Feb 12th 2013 ]: Market Wire
BioSyent Presents at MicroCapClub Invitational
[ Tue, Feb 12th 2013 ]: Market Wire
AcelRx Appoints Adrian Adams to Board of Directors as Chairman
[ Tue, Feb 12th 2013 ]: Market Wire
Lorus Therapeutics to Present LOR-253 Data at 2013 AACR Annual Meeting
[ Tue, Feb 12th 2013 ]: Market Wire
Biota Pharmaceuticals Reports Second Quarter Financial Results and Corporate Update
[ Tue, Feb 12th 2013 ]: Market Wire
Sirona Biochem's Cosmetic Skin Lightening Compoun .. s Proven Safe in Industry Standard Irritant Study
[ Tue, Feb 12th 2013 ]: Market Wire
Comprehensive Care Corporation Announces New Medi .. tract with Humana Health Plan of California, Inc.
Mon, February 11, 2013
[ Mon, Feb 11th 2013 ]: Market Wire
Quest Diagnostics Names Tracy L. Cinco-Abela Vice President and Treasurer
[ Mon, Feb 11th 2013 ]: Market Wire
Cytomedix Announces Approval of Angel cPRP System in Australia
[ Mon, Feb 11th 2013 ]: Market Wire
Thoratec Presentation at Leerink Swann Global Healthcare Conference to Be Webcast
[ Mon, Feb 11th 2013 ]: Market Wire
NW Bio To Present At 15th Annual BIO CEO amp;; Investor Conference
[ Mon, Feb 11th 2013 ]: Market Wire
Accuray Incorporated's CEO to Speak at Leerink Swan Global Healthcare Conference
[ Mon, Feb 11th 2013 ]: Market Wire
Vasomedical, Inc. Investor Presentation Now Avail .. n-demand Viewing at RetailInvestorConferences.com
[ Mon, Feb 11th 2013 ]: Market Wire
Life Technologies Receives FDA 510(k) Clearance f .. of Sanger Sequencing Platform and HLA Typing Kits
[ Mon, Feb 11th 2013 ]: Market Wire
Depomed Announces Appointment of Vicente J. Anido .. ctors, and Retirement of Directors Julian N. Ster
[ Mon, Feb 11th 2013 ]: Market Wire
AMRI Signs Agreement for Exclusive License of its Tubulin Inhibitor Program for Cancer
[ Mon, Feb 11th 2013 ]: Market Wire
An Undervalued Investment and Catalyst Trade Opportunity
[ Mon, Feb 11th 2013 ]: Market Wire
Mylan Appoints Melina Higgins and Rajiv Malik to Board of Directors
[ Mon, Feb 11th 2013 ]: Market Wire
Horizon Pharma Announces Preliminary Fourth Quart .. s, Full U.S. Commercial Launch of RAYOS(R) (Predn
[ Mon, Feb 11th 2013 ]: Market Wire
MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
[ Mon, Feb 11th 2013 ]: Market Wire
Aethlon Medical, Inc. Investor Presentation Now A .. n-demand Viewing at RetailInvestorConferences.com
[ Mon, Feb 11th 2013 ]: Market Wire
Ampio forms Luoxis Diagnostics to Commercialize ORP Technology
[ Mon, Feb 11th 2013 ]: Market Wire
Zynga, Inc. Fourth-Quarter Earnings and Sales Topped Wall Street Estimates
Sun, February 10, 2013
[ Sun, Feb 10th 2013 ]: Market Wire
Helix BioPharma Announces Director Resignation
Fri, February 8, 2013
[ Fri, Feb 08th 2013 ]: Market Wire
La Administracin de Alimentos y Medicamentos de E .. idomida) para el tratamiento de pacientes con mie
[ Fri, Feb 08th 2013 ]: Market Wire
US-amerikanische FDA erteilt Zulassung fr POMALYS .. ng von Patienten mit rezidiviertem und refraktrem
[ Fri, Feb 08th 2013 ]: Market Wire
US-amerikanische FDA erteilt Zulassung fr POMALYS .. ng von Patienten mit rezidiviertem und refraktrem
[ Fri, Feb 08th 2013 ]: Market Wire
US-amerikanische FDA erteilt Zulassung fr POMALYS .. ng von Patienten mit rezidiviertem und refraktrem
[ Fri, Feb 08th 2013 ]: Market Wire
US-amerikanische FDA erteilt Zulassung fr POMALYS .. ng von Patienten mit rezidiviertem und refraktrem
[ Fri, Feb 08th 2013 ]: Market Wire
US-amerikanische FDA erteilt Zulassung fr POMALYS .. ng von Patienten mit rezidiviertem und refraktrem
[ Fri, Feb 08th 2013 ]: Market Wire
RepliCel Announces Re-Pricing of Warrants
[ Fri, Feb 08th 2013 ]: Market Wire
Gilead Sciences schliet bernahme von YM BioSciences ab
[ Fri, Feb 08th 2013 ]: Market Wire
Harwood Feffer LLP Announces Investigation of Keryx Biopharmaceuticals, Inc.
[ Fri, Feb 08th 2013 ]: Market Wire
Quest Diagnostics To Speak At The Leerink Swann Global Healthcare Conference 2013
[ Fri, Feb 08th 2013 ]: Market Wire
WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
[ Fri, Feb 08th 2013 ]: Market Wire
The Medicines Company and Bristol-Myers Squibb Begin Global Alliance for Recothrom(R)
[ Fri, Feb 08th 2013 ]: Market Wire
Verisante Technology, Inc. Retains Hamza Thindal Capital Corp. for Investor Relations
[ Fri, Feb 08th 2013 ]: Market Wire
Amgen Announces Call For Nominations For 2013 Breakaway From Cancer Champions
[ Fri, Feb 08th 2013 ]: Market Wire
Strategic Global Investments, Inc. Announces the .. uction on 100 Video Segments Targeting the Employ

Helix BioPharma Announces Director Resignation

February 10, 2013 11:01 ET

Helix BioPharma Announces Director Resignation

AURORA, ON--(Marketwire - Feb 10, 2013) -  Helix BioPharma Corp. (TSX: [ HBP ]) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announced that on Friday, February 8, 2013 John A. Rogers has voluntarily resigned from Helix's board of directors.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP."